Literature DB >> 22115832

The use of PIB-PET as a dual pathological and functional biomarker in AD.

Anton Forsberg1, Henry Engler, Gunnar Blomquist, Bengt Långström, Agneta Nordberg.   

Abstract

Amyloid imaging with positron emission tomography (PET) is presently used in Alzheimer's disease (AD) research. In this study we investigated the possibility to use early frames (ePIB) of the PIB scans as a rough index of CBF by comparing normalised early PIB values with cerebral glucose metabolism (rCMRglc). PIB-PET and FDG-PET were performed in 37 AD patients, 21 subjects with mild cognitive impairment (MCI) and 6 healthy controls (HC). The patients were divided based on their PIB retention (amyloid load) as either PIB positive (PIB+) or PIB negative (PIB-). Data of the unidirectional influx K(1) from a subset of the subjects including 7 AD patients and 3 HC was used for correlative analysis. Data was analysed using regions of interest (ROI) analysis. A strong, positive correlation was observed across brain regions between K(1) and ePIB (r=0.70; p≤0.001). The ePIB values were significantly lower in the posterior cingulate (p≤0.001) and the parietal cortices (p=0.002) in PIB+ subjects compared to PIB-, although the group difference were stronger for rCMRglc in cortical areas (p≤0.001). Strong positive correlations between ePIB and rCMRglc were observed in all cortical regions analysed, especially in the posterior cingulate and parietal cortices (p≤0.001). A single dynamic PIB-PET scan may provide information about pathological and functional changes (amyloidosis and impaired blood flow). This might be important for diagnosis of AD, enrichment of patients in clinical trials and evaluation of treatment effects. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22115832     DOI: 10.1016/j.bbadis.2011.11.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  22 in total

1.  Early Phase PIB-PET as a Surrogate for Global and Regional Cerebral Blood Flow Measures.

Authors:  Laura L Boles Ponto; David J Moser; Yusuf Menda; Emily L Harlynn; Sean D DeVries; Jacob J Oleson; Vincent A Magnotta; Susan K Schultz
Journal:  J Neuroimaging       Date:  2018-11-21       Impact factor: 2.486

2.  Evaluation of two automated methods for PET region of interest analysis.

Authors:  Martin Schain; Katarina Varnäs; Zsolt Cselényi; Christer Halldin; Lars Farde; Andrea Varrone
Journal:  Neuroinformatics       Date:  2014-10

3.  Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images with [18F]FDG positron emission tomography in Alzheimer's disease.

Authors:  Elena Rodriguez-Vieitez; Antoine Leuzy; Konstantinos Chiotis; Laure Saint-Aubert; Anders Wall; Agneta Nordberg
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

4.  Dual-phase amyloid PET: hitting two birds with one stone.

Authors:  Garibotto Valentina; Morbelli Silvia; Pagani Marco
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-23       Impact factor: 9.236

5.  Longitudinal evaluation of surrogates of regional cerebral blood flow computed from dynamic amyloid PET imaging.

Authors:  Murat Bilgel; Lori Beason-Held; Yang An; Yun Zhou; Dean F Wong; Susan M Resnick
Journal:  J Cereb Blood Flow Metab       Date:  2019-02-12       Impact factor: 6.200

6.  Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis.

Authors:  Liping Fu; Linwen Liu; Jinming Zhang; Baixuan Xu; Yong Fan; Jiahe Tian
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

7.  Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.

Authors:  Solveig Tiepolt; Swen Hesse; Marianne Patt; Julia Luthardt; Matthias L Schroeter; Karl-Titus Hoffmann; David Weise; Hermann-Josef Gertz; Osama Sabri; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-30       Impact factor: 9.236

8.  Dynamic Amyloid PET: Relationships to 18F-Flortaucipir Tau PET Measures.

Authors:  Fabio Raman; Yu-Hua Dean Fang; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; John C Morris; Parinaz Massoumzadeh; Tammie Benzinger; Erik D Roberson; Jonathan McConathy
Journal:  J Nucl Med       Date:  2021-05-28       Impact factor: 10.057

9.  The clinical use of blood-test factors for Alzheimer's disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit.

Authors:  Haeng Jun Kim; Jong-Chan Park; Keum Sim Jung; Jiyeong Kim; Ji Sung Jang; Sunghoon Kwon; Min Soo Byun; Dahyun Yi; Gihwan Byeon; Gijung Jung; Yu Kyeong Kim; Dong Young Lee; Sun-Ho Han; Inhee Mook-Jung
Journal:  Exp Mol Med       Date:  2021-06-09       Impact factor: 8.718

Review 10.  Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease.

Authors:  Benoît Leclerc; Abedelnasser Abulrob
Journal:  ScientificWorldJournal       Date:  2013-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.